Download Report

Pharmacological Evaluation of ASP8273, a Mutant

Pharmacological Evaluation of ASP8273, a Mutant

TIGER 1: A randomized, open-label, phase 2/3

TIGER 1: A randomized, open-label, phase 2/3

Predominance of EGFR mutations responsible for resistance to

Predominance of EGFR mutations responsible for resistance to

Novel EGFR Inhibitors in the Setting of Acquired

Novel EGFR Inhibitors in the Setting of Acquired

A healthcare professional’s guide to managing skin toxicities during EGFR-inhibitor therapy

A healthcare professional’s guide to managing skin toxicities during EGFR-inhibitor therapy

Integrated research in STAT3 in cancer stem cells. Early adaptive

Integrated research in STAT3 in cancer stem cells. Early adaptive

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D.

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D.

Patient Name

Patient Name

Battling Brain Tumors - National Brain Tumor Society

Battling Brain Tumors - National Brain Tumor Society

Eric P. Pourmand, MD Jake H. Abernathy III, MD, MPH CA‐2 Resident Faculty Advisor

Eric P. Pourmand, MD Jake H. Abernathy III, MD, MPH CA‐2 Resident Faculty Advisor

SmartFlare for live cell RNA detection by using flow cytometry TM

SmartFlare for live cell RNA detection by using flow cytometry TM

Insulin-like growth factor 1 (IGF1R)/insulin

Insulin-like growth factor 1 (IGF1R)/insulin

© Copyright 2026